AGN's Principal Activity is the research and development of a neuroprotective therapeutic drug.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||+148.55%|
Argenica Therapeutics Limited (AGN) is into research and development of a neuroprotective therapeutic drug. The Company is developing novel neuroprotective therapeutics to reduce brain damage after stroke.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Dr Liz Dallimore||Chief Executive Officer,Managing Director||Apr 2022||
Dr Liz Dallimore
Chief Executive Officer,Managing Director
Dr Dallimore has over 20 years' experience across Australia and the UK with focus on research & development, innovation and commercialisation. Prior to joining Argenica Therapeutics, Dr Dallimore was the Director of the WA Data Science Innovation Hub, tasked with working across WA businesses to establish innovative data science projects. Dr Dallimore has also held senior roles in management consulting across Australia, most recently as KPMG's National Director of Research Engagement and Commercialization. Prior to this she held senior roles with Ernst & Young and PricewaterhouseCoopers. Dr Dallimore is a co-founder of medical device company Inspiring Holdings, sits on the AusBiotech WA Committee and is a non-executive Director of NERA, a Federal Government Growth Centre. She has worked as a neuroscientist at the Australian Neuromuscular Research Institute (now Perron Institute).
|Mr Terrence (Terry) Charles Budge||Non-Executive Director||Jan 2021||
Mr Terrence (Terry) Charles Budge
Mr Budge has experience in senior management and board roles. A long term banker he spent 25 years with National Australia Bank in senior executive roles before serving as Managing Director of Bankwest from 1997 to 2004. Since then he has had many non-executive director roles including Chancellor of Murdoch University from 2006 to 2013. Terry is currently a director or Tiller Rides. He is the Chair of Risk Committee.
|Ms Elizabeth (Liddy) McCall||Non-Executive Director||Dec 2020||
Ms Elizabeth (Liddy) McCall
Ms McCall is co-founder of 3 biotechnology companies successfully achieving 3 FDA drug registrations and 1 FDA/CE Mark medical device approval. She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment currently in Phase 2 clinical trials. Liddy cofounded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of 6 companies commercializing biotechnology and IT innovation. Liddy has over 25 years of experience in senior Board and management roles including Adalta Ltd, iCeutica Inc group, Dimerix Bioscience Pty Ltd and iCetana Pty Ltd. Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm. Liddy is a non-executive director of the not-for profit Ear Science Institute Australia and also of Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited. She is a member of Audit & Risk Committee.
|Dr Samantha (Sam) South||Executive Director||Mar 2020||
Dr Samantha (Sam) South
Dr South is currently the Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation office at The University of Western Australia (UWA) and has over 12 years' experience in technology transfer in medtech / biotech sector, at The University of Queensland (UQ), Queensland University of Technology and UWA. Sam has background in medical research at Weill Medical College at Cornell University (NY), UQ and The Garvan Institute in CNS research. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specialising in central nervous system animal models. Sam was the UWA Director on UWA spin-out companies MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Sam is also WA Ausbiotech Committee Chair, part of the Ausmedtech National Advisory Group and the SBE Life Sciences Council.
|Mr Geoffrey (Geoff) Richard Pocock||Non-Executive Chairman,Non-Executive Director||Nov 2019||
Mr Geoffrey (Geoff) Richard Pocock
Non-Executive Chairman,Non-Executive Director
Mr Pocock has over 20 years experience across the commercialisation process. Geoff's experience has covered technical roles, executive management as well as significant corporate finance and strategy roles with a number of technology commercialisation ventures. Geoff is the Principal of Polaris Consulting (WA) Pty Ltd, a specialist boutique commercialisation strategy and corporate advisory business based in Western Australia. He is a member of Risk Committee.
|Ms Emma Waldon||Chief Financial Officer,Company Secretary||N/A|
AGN directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|25/02/22||Terrence (Terry) Budge||Buy||+32,520||$0.639||$20,786||On-market trade|
The current holdings of AGN directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Terrence (Terry) Budge||25/02/2022||N/A||487,520||500,000||N/A|
|Samantha (Sam) South||30/06/2021||N/A||2,000,000||1,000,000||N/A|
|Geoffrey (Geoff) Pocock||30/06/2021||N/A||4,377,000||500,000||N/A|
|Elizabeth (Liddy) McCall||30/06/2021||N/A||125,000||500,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|University of Western Australia||25/08/2021||3,953,000||5.40|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.